Meloxicam (Metacam)

Meloxicam is a nonsteroidal anti-inflammatory drug belonging to the oxicam class that has become one of the most widely used analgesics in farm animal medicine. This medication provides effective pain relief, reduces inflammation, and lowers fever in cattle, sheep, goats, and pigs. Meloxicam has gained significant popularity in livestock production due to its favorable safety profile, relatively long duration of action, and proven efficacy in managing pain associated with common husbandry procedures and disease conditions.

The mechanism of action of meloxicam involves preferential inhibition of the cyclooxygenase-2 (COX-2) enzyme, which is primarily responsible for producing prostaglandins at sites of inflammation and tissue injury. By blocking COX-2 activity, meloxicam reduces the production of inflammatory mediators that cause pain, swelling, and fever. This COX-2 preferential activity is considered advantageous because it provides anti-inflammatory effects while causing less disruption to the protective prostaglandins produced by COX-1, which help maintain normal gastrointestinal and kidney function.

Meloxicam is available in several formulations suitable for farm animal use, including injectable solutions for subcutaneous or intravenous administration and oral suspensions for convenient dosing. The injectable formulation is most commonly used in cattle and pigs, while oral formulations may be utilized in smaller ruminants and for follow-up treatment. The drug demonstrates excellent bioavailability regardless of the route of administration, reaching peak plasma concentrations within hours and maintaining therapeutic levels for an extended period that supports once-daily dosing in most species.

From a regulatory standpoint, meloxicam has received approval for use in food-producing animals in many countries, though specific indications and withdrawal times vary by region. In the European Union, meloxicam is approved for cattle, pigs, and horses, while in other regions it may be used under extra-label drug provisions with appropriate veterinary oversight. The establishment of maximum residue limits and defined withdrawal periods has facilitated the legitimate use of meloxicam in food animals while ensuring consumer safety. Veterinary supervision is essential for proper use, and a valid veterinarian-client-patient relationship must be established before prescribing this medication for any food-producing animal.

Meloxicam is indicated for the management of pain and inflammation associated with a wide range of conditions in farm animals. The primary labeled indications include treatment of acute respiratory disease in cattle, where meloxicam reduces fever and alleviates the discomfort associated with pneumonia and other respiratory infections. When used in conjunction with appropriate antimicrobial therapy, meloxicam has been shown to improve treatment outcomes, enhance appetite, and accelerate recovery in calves and adult cattle suffering from bovine respiratory disease complex.

In cattle production, meloxicam is extensively used to provide analgesia during and after painful husbandry procedures. Dehorning, castration, and branding cause significant pain and stress that can negatively impact animal welfare and productivity. Administration of meloxicam before or at the time of these procedures has been demonstrated to reduce pain behaviors, maintain normal feeding patterns, and minimize the stress response. Many progressive livestock operations now routinely include meloxicam as part of their standard protocols for painful procedures to align with modern animal welfare standards.

Mastitis represents another important indication for meloxicam use in dairy cattle. The intense inflammation and pain associated with clinical mastitis causes significant suffering and reduces milk production. Meloxicam administration alongside antimicrobial therapy helps reduce udder inflammation, alleviates pain, and may improve cure rates. Cows treated with meloxicam during mastitis episodes typically show faster recovery, better appetite, and improved milk yield following resolution of the infection. The anti-inflammatory effects also help protect the udder tissue from permanent damage caused by excessive inflammatory responses.

In sheep, goats, and pigs, meloxicam is used to manage pain and inflammation associated with various conditions including lameness, respiratory disease, and surgical procedures. Lameness in sheep and goats, whether caused by foot rot, interdigital dermatitis, or traumatic injury, responds well to meloxicam therapy combined with appropriate treatment of the underlying cause. The drug helps maintain mobility and feeding behavior during the recovery period. In swine, meloxicam is used for respiratory disease, mastitis-metritis-agalactia syndrome, and as part of pain management protocols for processing procedures in piglets.

Extra-label uses of meloxicam in farm animals extend to various painful conditions including musculoskeletal injuries, post-surgical pain management, and supportive care for animals with infectious diseases. Veterinarians may prescribe meloxicam for conditions such as traumatic injuries, joint infections, or as adjunctive therapy for animals with severe systemic illness. All extra-label use must comply with applicable regulations, and extended withdrawal times must be observed to ensure food safety. The versatility of meloxicam and its favorable safety profile have made it an essential tool in the farm animal veterinarian's arsenal for managing pain and promoting animal welfare.

The recommended dosage of meloxicam varies by species and the specific product formulation being used. In cattle, the standard dose is 0.5 mg per kilogram of body weight, administered as a single subcutaneous or intravenous injection. This dose provides effective analgesia for approximately 72 hours, making it suitable for most acute pain conditions and procedural analgesia. For acute respiratory disease in cattle, meloxicam should be administered at the time of diagnosis in conjunction with appropriate antimicrobial therapy. When used for painful procedures such as dehorning or castration, meloxicam should ideally be given 10 to 20 minutes before the procedure to allow the drug to reach therapeutic levels, or alternatively at the time of the procedure.

In sheep and goats, meloxicam is typically administered at a dose of 0.5 to 1.0 mg per kilogram of body weight, depending on the specific indication and product label. The subcutaneous route is preferred in small ruminants, with injection given in the neck region behind the ear. Due to the smaller body size of sheep and goats, accurate weight estimation is important to ensure proper dosing. For lameness conditions, treatment may be repeated after 24 to 48 hours if pain persists, though extended treatment courses require veterinary evaluation to address the underlying cause.

Swine dosing of meloxicam is generally 0.4 mg per kilogram of body weight, administered intramuscularly in the neck region. In piglets undergoing processing procedures such as castration, tail docking, or teeth clipping, meloxicam should be administered before or at the time of the procedure. For sows with mastitis-metritis-agalactia syndrome, meloxicam is administered as a single injection to reduce fever and inflammation while other supportive treatments are initiated. The intramuscular route is preferred in pigs due to the anatomy and handling considerations specific to this species.

Proper administration technique is critical for ensuring drug efficacy and minimizing injection site reactions. For subcutaneous injection in cattle, the drug should be deposited under the skin in the neck region using appropriate needle size and sterile technique. Intravenous administration requires proper venipuncture technique and should be performed slowly over several seconds. The injectable solution should be at room temperature before administration, and multi-dose vials should be handled with aseptic technique to prevent contamination. Maximum injection volumes should not exceed 10 mL per injection site in adult cattle, with smaller volumes appropriate for calves and smaller species.

Oral formulations of meloxicam are available and may be used for follow-up treatment or in situations where injection is not practical. The oral suspension should be administered directly into the mouth using a dosing syringe, with care taken to ensure the animal swallows the medication. Oral meloxicam is well absorbed in ruminants, though the time to peak effect is somewhat longer than with injectable administration. For animals that are not eating well, injectable administration is preferred to ensure reliable drug absorption.

Withdrawal times for meloxicam must be strictly observed before animals or their products enter the food supply. In cattle, the meat withdrawal time is typically 15 to 20 days depending on the specific product and regional regulations, while the milk withdrawal time is generally 5 days. Sheep and goat withdrawal times are similar, typically 15 days for meat and 5 days for milk. In pigs, the meat withdrawal time is usually 5 days. These withdrawal periods may be extended when meloxicam is used in an extra-label manner, and veterinarians should consult the Food Animal Residue Avoidance Databank for guidance on appropriate withdrawal intervals. Accurate record-keeping of all meloxicam administration is essential to ensure compliance with withdrawal requirements.

Meloxicam is generally well tolerated in farm animals when used according to label directions, with a relatively low incidence of adverse effects compared to some other NSAIDs. The COX-2 preferential activity of meloxicam provides anti-inflammatory benefits while offering some degree of protection against the gastrointestinal side effects commonly associated with non-selective NSAIDs. However, as with all medications, side effects can occur, and producers and veterinarians should be aware of the potential adverse reactions associated with meloxicam use.

Gastrointestinal effects represent the most commonly reported side effects of meloxicam in farm animals. These may include decreased appetite, mild diarrhea, or changes in fecal consistency. While meloxicam is less likely to cause gastrointestinal ulceration than non-selective NSAIDs, prolonged use or use in dehydrated or stressed animals may increase the risk of gastrointestinal complications. Young calves and animals with pre-existing gastrointestinal disease may be more susceptible to these effects. Monitoring appetite and fecal output during treatment helps identify animals that may be experiencing gastrointestinal side effects.

Injection site reactions can occur following subcutaneous or intramuscular administration of meloxicam. These reactions are typically mild and transient, consisting of localized swelling or sensitivity at the injection site that resolves within a few days. Proper injection technique, including use of appropriate needle size, injection of proper volumes, and administration in the recommended anatomical sites, helps minimize the occurrence of injection site reactions. Severe injection site reactions are rare but should be reported to the prescribing veterinarian.

Renal effects are a potential concern with any NSAID, including meloxicam. Prostaglandins play an important role in maintaining renal blood flow, particularly in animals that are dehydrated, hypovolemic, or experiencing cardiovascular compromise. Administration of meloxicam to animals in these conditions may impair kidney function and potentially lead to acute renal failure. Animals should be adequately hydrated before receiving meloxicam, and the drug should be used with caution in animals with pre-existing kidney disease, heart failure, or conditions that may compromise renal perfusion. Monitoring urine output and hydration status is advisable when treating sick animals with meloxicam.

Other potential side effects of meloxicam in farm animals include prolonged bleeding times due to inhibition of platelet function and, rarely, hypersensitivity reactions. Animals undergoing surgery should be monitored for excessive bleeding if meloxicam has been administered perioperatively. Signs of hypersensitivity reaction may include facial swelling, hives, respiratory distress, or collapse, and require immediate veterinary attention. Species-specific toxicities are uncommon with meloxicam at recommended doses, but individual animal variation in drug metabolism may occasionally result in unexpected adverse effects. Any unusual signs observed following meloxicam administration should be reported to the veterinarian, and treatment should be discontinued if serious adverse effects occur.

Meloxicam is contraindicated in animals with known hypersensitivity to meloxicam or other NSAIDs. Animals that have previously exhibited allergic reactions to any NSAID, including aspirin, should not receive meloxicam due to the potential for cross-reactivity within this drug class. Signs of NSAID hypersensitivity may include facial swelling, hives, difficulty breathing, or anaphylaxis, and any history of such reactions should be carefully documented and communicated to all personnel involved in animal care.

The use of meloxicam is contraindicated in animals with active gastrointestinal ulceration or bleeding. NSAIDs can inhibit the production of protective prostaglandins in the gastrointestinal tract, potentially worsening existing ulcers or causing new ones to develop. Animals with a history of gastrointestinal ulceration should be treated with meloxicam only when the potential benefits clearly outweigh the risks, and alternative pain management strategies should be considered when available. Similarly, meloxicam should not be used in animals with evidence of internal hemorrhage or conditions associated with bleeding tendencies.

Meloxicam should not be administered to animals with significant renal impairment or those at high risk for kidney injury. Animals that are severely dehydrated, hypovolemic, or in shock require fluid resuscitation and stabilization before NSAID therapy can be safely initiated. The concurrent administration of other nephrotoxic drugs increases the risk of kidney damage and should be avoided when possible. Animals with pre-existing chronic kidney disease may be at increased risk for acute-on-chronic renal failure with NSAID use and require careful evaluation before treatment.

Production stage restrictions apply to meloxicam use in food-producing animals. While meloxicam is generally considered safe during pregnancy and lactation when used at recommended doses, specific product labels may contain restrictions regarding use in pregnant or lactating animals. Producers should verify that the meloxicam product being used is approved for the specific production stage of the animals being treated. Additionally, meloxicam should not be used in animals intended for slaughter before the required withdrawal time has elapsed, and accurate treatment records must be maintained to ensure compliance with food safety regulations. Animals intended for immediate sale or slaughter should not be treated with meloxicam unless appropriate withdrawal periods can be observed.

Meloxicam has the potential for significant drug interactions that must be considered when developing treatment protocols for farm animals. The most important interaction to avoid is concurrent administration of multiple NSAIDs, as this significantly increases the risk of gastrointestinal ulceration, renal toxicity, and other adverse effects without providing additional therapeutic benefit. Animals should not receive meloxicam if they have been treated with another NSAID within the previous 24 to 48 hours, and NSAID therapy should not be overlapped or stacked under any circumstances. This includes avoiding concurrent use with aspirin, flunixin meglumine, ketoprofen, or any other NSAID.

The interaction between NSAIDs and corticosteroids is of particular concern in farm animal medicine. Concurrent administration of meloxicam with corticosteroids such as dexamethasone dramatically increases the risk of gastrointestinal ulceration and bleeding. While both drug classes may be indicated for inflammatory conditions, they should generally not be given together. If both an NSAID and corticosteroid are needed, a washout period of at least 24 hours between drugs is recommended, though this may vary based on the specific drugs and clinical situation. Veterinary guidance should be sought when managing cases that might benefit from both anti-inflammatory classes.

Meloxicam may interact with drugs that affect renal function or are eliminated primarily through the kidneys. Aminoglycoside antibiotics, commonly used in farm animal medicine, are nephrotoxic and should be used cautiously in combination with meloxicam. Adequate hydration and monitoring of kidney function are advisable when these drugs must be used together. Similarly, diuretics may interact with meloxicam by altering kidney perfusion and electrolyte balance. Animals receiving concurrent diuretic therapy should be monitored closely for signs of dehydration or kidney dysfunction.

Interactions with highly protein-bound drugs may occur because meloxicam binds extensively to plasma proteins. Concurrent administration with other highly protein-bound medications could theoretically result in displacement and increased free drug concentrations of either medication. While clinically significant interactions of this type are uncommon in farm animals, veterinarians should be aware of this potential when prescribing meloxicam alongside other medications. Sulfonamides, some antimicrobials, and anticoagulants are examples of highly protein-bound drugs used in livestock. The combination of meloxicam with anticoagulant drugs may increase bleeding risk due to additive effects on platelet function and should be avoided when possible.

Human safety precautions must be observed when handling and administering meloxicam to farm animals. Individuals with known hypersensitivity to NSAIDs should avoid direct contact with the product and should wear protective gloves during administration. Accidental self-injection is a risk with any injectable medication, and care should be taken to ensure proper restraint of animals and use of appropriate injection technique. In the event of accidental self-injection, medical attention should be sought immediately, and the product label or safety data sheet should be provided to the treating physician. Pregnant women should exercise particular caution, as NSAIDs may affect fetal development.

Food safety and residue avoidance represent critical concerns when using meloxicam in food-producing animals. Strict adherence to withdrawal times is mandatory, and producers must maintain accurate records of all treatments including the date of administration, animal identification, dose administered, and calculated withdrawal date. Animals should not be sent to slaughter, and milk should not be sold for human consumption, until the appropriate withdrawal time has elapsed. When meloxicam is used in an extra-label manner, extended withdrawal times may be necessary, and consultation with a veterinarian or the Food Animal Residue Avoidance Databank is recommended to determine appropriate intervals.

Environmental considerations should be taken into account when disposing of meloxicam products and treated animal waste. Unused medication should be disposed of according to local regulations, and empty containers should not be reused for any purpose. The environmental fate and effects of meloxicam excreted by treated animals are not fully characterized, and general principles of environmental stewardship should be applied. This includes proper management of manure from treated animals and avoiding contamination of waterways.

Antimicrobial resistance is not a direct concern with meloxicam since it is not an antimicrobial agent. However, the judicious use of all veterinary medications supports overall efforts to maintain drug efficacy and reduce resistance development. Meloxicam should be used as part of a comprehensive treatment plan developed by a veterinarian, and should not be used as a substitute for proper diagnosis and treatment of underlying conditions. Pain management is an important component of animal welfare, but does not replace the need for appropriate antimicrobial therapy when bacterial infections are present.

Proper use protocols help ensure that meloxicam remains an effective and safe tool for managing pain in farm animals. The drug should only be used under veterinary supervision and in accordance with a valid veterinarian-client-patient relationship. Accurate diagnosis of the underlying condition is essential before initiating treatment, as pain relief may mask signs of progressive disease. Animals receiving meloxicam should be monitored for treatment response and adverse effects, and treatment plans should be adjusted based on clinical progress. Long-term or repeated use of meloxicam should be avoided unless clearly indicated and supervised by a veterinarian.

Meloxicam injectable solutions should be stored according to the manufacturer's specifications, typically at controlled room temperature between 15 and 30 degrees Celsius. The product should be protected from light and kept in the original container until use. Freezing should be avoided, as this may alter the physical properties of the solution and affect drug stability. Prior to administration, the solution should be visually inspected for particulate matter, discoloration, or other abnormalities, and any product that appears abnormal should not be used.

Multi-dose vials of meloxicam require careful handling to maintain sterility and product integrity throughout the use period. Aseptic technique should be employed when withdrawing doses, using sterile needles and avoiding contamination of the vial septum. The broaching date should be recorded on the vial, and the product should be used within the timeframe specified by the manufacturer after first use, typically 28 days. Needles should never be left in the vial septum, and any vials showing signs of contamination should be discarded. Drawing up doses in advance and storing filled syringes is not recommended, as this increases the risk of contamination and may affect drug stability.

Disposal of meloxicam products and associated materials must follow local, state, and federal regulations for pharmaceutical waste. Unused medication should not be poured down drains or disposed of in regular trash. Many areas have pharmaceutical take-back programs or approved disposal methods for veterinary medications. Empty containers should be triple-rinsed if required by local regulations and disposed of according to container label instructions. Needles and syringes used for administration should be placed in approved sharps containers and disposed of through appropriate medical waste channels. Product safety data sheets should be maintained and available for reference regarding specific disposal requirements and emergency response procedures.

Species-specific dosing considerations are essential when using meloxicam in diverse farm animal populations. Cattle generally receive meloxicam at 0.5 mg per kilogram, but accurate weight estimation is important to ensure proper dosing. Visual estimation of cattle weight is notoriously inaccurate, and use of scales or weight tapes is recommended when possible. Young calves may have different pharmacokinetics than adult cattle, and veterinary guidance should be sought for treatment of very young animals. Beef and dairy cattle may be treated similarly, though attention to appropriate withdrawal times for meat versus milk is essential.

Sheep and goats present unique considerations for meloxicam use. While both species are small ruminants, their metabolism and drug sensitivities can differ significantly. Goats generally metabolize drugs more rapidly than sheep and may require higher or more frequent doses of some medications, though meloxicam dosing is generally similar between species. The smaller body size of sheep and goats requires more precise dose calculation and the use of appropriately sized syringes for accurate measurement. Accurate weighing of individual animals or representative samples from a group is recommended to ensure proper dosing.

Production type considerations influence meloxicam use protocols. Dairy cattle have specific milk withdrawal requirements that must be observed, and meloxicam should only be used in lactating dairy cattle when the milk withdrawal period can be properly managed. Beef cattle intended for near-term slaughter should not be treated with meloxicam unless the meat withdrawal time can be observed. Breeding animals receiving meloxicam should be monitored for any effects on reproductive performance, though meloxicam is generally considered safe for use in breeding animals at recommended doses.

Age and weight considerations are important across all farm animal species. Very young animals may have immature organ systems that affect drug metabolism and elimination, potentially requiring dose adjustment or extended monitoring. Geriatric animals may have reduced kidney or liver function that affects drug clearance, and lower doses or extended dosing intervals may be appropriate. Extremely thin or debilitated animals may be at increased risk for adverse effects and should be carefully evaluated before initiating meloxicam therapy. Proper hydration status should be ensured in all animals before NSAID administration, regardless of age or production stage.

Several other NSAIDs are available for use in farm animals and may be considered as alternatives to meloxicam depending on the clinical situation, availability, and species being treated. Flunixin meglumine is widely used in cattle and pigs for pain and fever management, with well-established efficacy in bovine respiratory disease and endotoxemia. Flunixin has a shorter duration of action than meloxicam and may require more frequent dosing, but offers the advantage of intravenous administration for rapid effect. Ketoprofen is another NSAID option approved for use in some farm animal species, with indications similar to meloxicam.

Within the same drug class, different formulations and brand products of meloxicam may be available depending on the region. Generic meloxicam products have become available in many markets, offering cost-effective alternatives to the original branded products. When selecting among meloxicam products, attention should be paid to approved species, concentrations, and specific withdrawal times, as these may vary between products. Only products approved for food-producing animals should be used in livestock, as companion animal formulations may not have established withdrawal times for meat and milk.

Combination approaches to pain management may be employed when meloxicam alone provides insufficient analgesia. Local anesthetics such as lidocaine provide immediate pain relief when administered at the surgical site and can be used in conjunction with meloxicam for procedures such as dehorning or castration. The combination of local anesthesia for immediate effect and meloxicam for extended post-procedural analgesia represents current best practice for painful husbandry procedures. Other analgesic options including alpha-2 agonists may be used for sedation and analgesia in specific situations, though these drugs have different mechanisms and indications than NSAIDs. A comprehensive pain management plan developed in consultation with a veterinarian provides the best outcomes for animal welfare.